You will prepare a PhD on a project that focuses on a novel factor that drives peripheral nerve myelination with a specific focus on Schwann cell biology. In addition to the fundamental aspects of this topic, you will evaluate the therapeutic potential of this factor in the context of peripheral demyelinating diseases, with a particular focus on Charcot-Marie-Tooth disease type 1A, the most prevalent inherited peripheral neuropathy causing demyelination.
To this end, we offer you:
The faculty of medicine and life sciences contributes to sustainable solutions for health-related issues as part of the civic Hasselt University. The faculty focuses on excellence in education and research and connects with society through a strong collaboration with our partners. Starting from continuous attention for quality and innovation, the faculty is a breeding ground and magnet for talent with an open view on society, from the region to the world.
The Biomedical Research Institute (BIOMED) of Hasselt University conducts high level multidisciplinary research to advance progress in human life sciences. High-end technology is used to deliver novel insights in three main disease areas: (neuro)immunology, neuroscience and cardiovascular disease. BIOMED aims to translate new scientific discoveries into applications that contribute to a healthy society in line with the civic ambition of Hasselt University.
This project is funded by FWO and is a collaboration between Prof. Dr. Niels Hellings (NIC&R lab) and Prof. Dr. Esther Wolfs (FIERCE lab), integrating expertise in de- and remyelination, Schwann cell biology, and Charcot-Marie-Tooth Disease type 1A (CMT1A). Within this stimulating environment, we are looking for a highly motivated PhD student. The project investigates the involvement of a novel factor in peripheral nerve myelination as well as its therapeutic potential for peripheral neuropathies, with a focus on CMT1A.
You will be appointed and paid as PhD student.
We offer you an appointment for a period of 2 years that will be extended for another 2 years, after positive evaluation.
You are encouraged to apply for mandate specific funding
The selection procedure consists of a preselection based on application file and an interview.
Apply now
Apply up to 03.03.2025